Navigation Links
Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences

CHAPEL HILL, N.C., April 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences.  Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego.  Her presentation is entitled "Macrolides as a New Class of Orally Active Anti-Inflammatory Agents." Her presentation will include a discussion on the mechanism of macrolide action as anti-inflammatory agents and the use of macrolides in COPD patients. Data on the potent anti-inflammatory activities of solithromycin (CEM-101), Cempra's fluoroketolide candidate in Phase 2 clinical development for community-acquired bacterial pneumonia (CABP), as well as novel macrolides without antibacterial activity will be presented.

Dr. Fernandes will present at the Fifth Annual Resistance is Futile: The Challenge of Antibacterial Drug Development Conference at 10:45 a.m. PDT, April 13, at the Hilton San Diego Resort in San Diego.  Her presentation is entitled "Solithromycin: A Well-Tolerated Fluoroketolide with Broad Spectrum, Potent Activity" and will provide an overview of the potential clinical value of an oral and intravenous macrolide in treating drug-resistant pathogens.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251

SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
3. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
4. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
5. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
7. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
8. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
9. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
10. Reportlinker Adds Global: Pharmaceuticals Industry Guide
11. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Post Your Comments:
(Date:12/1/2015)...  The migration to value-based care will require ... that help patients stay healthy and reduce healthcare ... enabled, incorporate care guidelines and be reflective of ... also allow all stakeholders to collaborate across care ... That is the vision, however, research by Chilmark ...
(Date:12/1/2015)... -- --> --> ... (NKI-AVL), among the world,s largest and most prestigious ... Icon™, the company,s latest generation stereotactic radiosurgery system ... --> With the option to use ... Knife Icon offers greatly enhanced flexibility in how ...
(Date:12/1/2015)... , December 1, 2015 ... segments the concerned market with analysis and forecast of ... orthobiologics report defines and segments the concerned market with ... to the Market Research Report "North American Orthobiologics Market ... Factors & Spinal Stimulation, Stem Cell Therapy, Viscosupplementation), by ...
Breaking Medicine Technology:
(Date:12/1/2015)... Middletown, PA (PRWEB) , ... December 01, 2015 ... ... separate environments; however, there are professionals who believe that with innovative technologies and ... services allows the patient to get the benefit of a dual-approach to his ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN ... today announced that the organization has awarded Education and Developmental Therapies (EDT), an ... Award. The award celebrates exceptional special needs providers that excel in synthesizing the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the care management and population health arenas, is pleased to announce that VIP ... containment services, has successfully implemented the ACUITY Complete Care™ Management to back their ...
Breaking Medicine News(10 mins):